(Q46105885)

19 December 2017

title

Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients (English)

1 reference

19 December 2017

0 references

1

J Malyszko

1 reference

19 December 2017

author name string

J S Malyszko

series ordinal

2

1 reference

19 December 2017

M Mysliwiec

series ordinal

3

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

19 December 2017

Transplantation Proceedings

published in

1 reference

19 December 2017

volume

41

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

150-153

1 reference

19 December 2017

Positional cloning of the mouse obese gene and its human homologue

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Serum visfatin concentration and endothelial dysfunction in chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Associations between circulating inflammatory markers and residual renal function in CRF patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with xenogeneic sponge molecule(s).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Visfatin, low-grade inflammation and body mass index (BMI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Molecular Characteristics of Serum Visfatin and Differential Detection by Immunoassays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

Circulating visfatin level is correlated with inflammation, but not with insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.086

10.1016/J.TRANSPROCEED.2008.10.086

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017